【西他沙星100mg / d的安全性和有效性研究——使用-结果调查结果】。

The Japanese journal of antibiotics Pub Date : 2014-06-01
Seiji Hori, Kazuhiro Uchino, Takuyuki Matsumoto, Hiroki Yamaguchi, Megumi Takahashi, Satoko Hamajima, Kaori Nukui, Hisano Eda, Akiko Shiina, Atsushi Takita, Naoki Yamanouchi, Masami Mizuno, Yukihiro Okutani
{"title":"【西他沙星100mg / d的安全性和有效性研究——使用-结果调查结果】。","authors":"Seiji Hori,&nbsp;Kazuhiro Uchino,&nbsp;Takuyuki Matsumoto,&nbsp;Hiroki Yamaguchi,&nbsp;Megumi Takahashi,&nbsp;Satoko Hamajima,&nbsp;Kaori Nukui,&nbsp;Hisano Eda,&nbsp;Akiko Shiina,&nbsp;Atsushi Takita,&nbsp;Naoki Yamanouchi,&nbsp;Masami Mizuno,&nbsp;Yukihiro Okutani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from December 2011 to May 2013. In total, 1,186 case cards were collected from 226 medical institutions and 1,089 cases were subjected to a safety evaluation and 1,069 were subjected to an efficacy evaluation. The incidence of adverse drug reactions (ADRs) was 2.11% (23/1,089 cases) and no serious ADRs were observed. The major ADR was diarrhea at 1.10% (12/1,089 cases). Of these 12 cases, 10 cases developed symptoms within 4 days of treatment. All of them, except one case that could not be followed up, either recovered or improved. Nonsteroidal anti-inflammatory drugs of the phenyl acetate and propionate types, which require caution when coadministered with STFX, were used concomitantly by 17.6% (192/1,089 cases) of patients but no central nervous system ADRs were observed. The overall efficacy rate was 96.4% (1,030/1,069 cases) and by types of infections, it was 97.0% (387/399 cases) for respiratory tract infections, 96.7% (353/365 cases) for urinary tract infections, 94.7% (36/38 cases) for gynecological infections, 92.3% (132/143 cases) for otorhinolaryngological infections, 98.4% (122/124 cases) for dental and oral surgical infections. The efficacy rate in every category of site of infection exceeded 90%. The overall eradication rate was 94.4% (185/196 strains) including Gram-positive bacteria at 95.4% (62/65 strains), Gram-negative bacteria at 92.2% (94/102 strains), anaerobes at 100.0% (11/11 strains) and atypical bacteria at 100.0% (18/18 strains). In conclusion, this use-results survey confirmed that STFX 100 mg/day is an effective administration with no serious problems in its safety profile and efficacy rate of over 90% in every category of site of infection.</p>","PeriodicalId":22536,"journal":{"name":"The Japanese journal of antibiotics","volume":"67 3","pages":"175-91"},"PeriodicalIF":0.0000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day--results of the use-results survey].\",\"authors\":\"Seiji Hori,&nbsp;Kazuhiro Uchino,&nbsp;Takuyuki Matsumoto,&nbsp;Hiroki Yamaguchi,&nbsp;Megumi Takahashi,&nbsp;Satoko Hamajima,&nbsp;Kaori Nukui,&nbsp;Hisano Eda,&nbsp;Akiko Shiina,&nbsp;Atsushi Takita,&nbsp;Naoki Yamanouchi,&nbsp;Masami Mizuno,&nbsp;Yukihiro Okutani\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from December 2011 to May 2013. In total, 1,186 case cards were collected from 226 medical institutions and 1,089 cases were subjected to a safety evaluation and 1,069 were subjected to an efficacy evaluation. The incidence of adverse drug reactions (ADRs) was 2.11% (23/1,089 cases) and no serious ADRs were observed. The major ADR was diarrhea at 1.10% (12/1,089 cases). Of these 12 cases, 10 cases developed symptoms within 4 days of treatment. All of them, except one case that could not be followed up, either recovered or improved. Nonsteroidal anti-inflammatory drugs of the phenyl acetate and propionate types, which require caution when coadministered with STFX, were used concomitantly by 17.6% (192/1,089 cases) of patients but no central nervous system ADRs were observed. The overall efficacy rate was 96.4% (1,030/1,069 cases) and by types of infections, it was 97.0% (387/399 cases) for respiratory tract infections, 96.7% (353/365 cases) for urinary tract infections, 94.7% (36/38 cases) for gynecological infections, 92.3% (132/143 cases) for otorhinolaryngological infections, 98.4% (122/124 cases) for dental and oral surgical infections. The efficacy rate in every category of site of infection exceeded 90%. The overall eradication rate was 94.4% (185/196 strains) including Gram-positive bacteria at 95.4% (62/65 strains), Gram-negative bacteria at 92.2% (94/102 strains), anaerobes at 100.0% (11/11 strains) and atypical bacteria at 100.0% (18/18 strains). In conclusion, this use-results survey confirmed that STFX 100 mg/day is an effective administration with no serious problems in its safety profile and efficacy rate of over 90% in every category of site of infection.</p>\",\"PeriodicalId\":22536,\"journal\":{\"name\":\"The Japanese journal of antibiotics\",\"volume\":\"67 3\",\"pages\":\"175-91\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Japanese journal of antibiotics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Japanese journal of antibiotics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

西他沙星(STFX, Gracevit 50 mg,细颗粒10%)是一种口服喹诺酮类抗菌剂,于2011年8月被批准以100 mg /天一次的剂量额外给药。2011年12月至2013年5月对STFX 100 mg/d进行了使用结果调查。从226家医疗机构共收集了1186例病例卡,对1089例进行了安全性评价,对1069例进行了疗效评价。药物不良反应(adr)发生率为2.11%(23/ 1089),未见严重不良反应发生。主要不良反应为腹泻,占1.10%(12/ 1089)。在这12例病例中,10例在治疗4天内出现症状。除1例无法随访外,其余患者均恢复或好转。17.6%(192/ 1089例)的患者同时使用非甾体类抗炎药醋酸苯酯和丙酸酯类抗炎药,但未观察到中枢神经系统不良反应。总有效率为96.4%(1030 / 1069例),按感染类型分,呼吸道感染97.0%(387/399例)、尿路感染96.7%(353/365例)、妇科感染94.7%(36/38例)、耳鼻喉科感染92.3%(132/143例)、口腔外科感染98.4%(122/124例)。各类感染部位的有效率均超过90%。总根除率为94.4%(185/196株),其中革兰氏阳性菌95.4%(62/65株),革兰氏阴性菌92.2%(94/102株),厌氧菌100.0%(11/11株),非典型菌100.0%(18/18株)。总之,这项使用结果调查证实,STFX 100 mg/天是一种有效的给药,其安全性没有严重问题,在每种感染部位的有效率都超过90%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day--results of the use-results survey].

Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from December 2011 to May 2013. In total, 1,186 case cards were collected from 226 medical institutions and 1,089 cases were subjected to a safety evaluation and 1,069 were subjected to an efficacy evaluation. The incidence of adverse drug reactions (ADRs) was 2.11% (23/1,089 cases) and no serious ADRs were observed. The major ADR was diarrhea at 1.10% (12/1,089 cases). Of these 12 cases, 10 cases developed symptoms within 4 days of treatment. All of them, except one case that could not be followed up, either recovered or improved. Nonsteroidal anti-inflammatory drugs of the phenyl acetate and propionate types, which require caution when coadministered with STFX, were used concomitantly by 17.6% (192/1,089 cases) of patients but no central nervous system ADRs were observed. The overall efficacy rate was 96.4% (1,030/1,069 cases) and by types of infections, it was 97.0% (387/399 cases) for respiratory tract infections, 96.7% (353/365 cases) for urinary tract infections, 94.7% (36/38 cases) for gynecological infections, 92.3% (132/143 cases) for otorhinolaryngological infections, 98.4% (122/124 cases) for dental and oral surgical infections. The efficacy rate in every category of site of infection exceeded 90%. The overall eradication rate was 94.4% (185/196 strains) including Gram-positive bacteria at 95.4% (62/65 strains), Gram-negative bacteria at 92.2% (94/102 strains), anaerobes at 100.0% (11/11 strains) and atypical bacteria at 100.0% (18/18 strains). In conclusion, this use-results survey confirmed that STFX 100 mg/day is an effective administration with no serious problems in its safety profile and efficacy rate of over 90% in every category of site of infection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信